Ivor Smajlagic, Rozhin Rowshanpour, Lea Milkin and Travis Dudding*
Received: June 15, 2020; Published: June 24, 2020
Corresponding author: Travis Dudding, Department of Chemistry, Brock University, St. Catharines, ON L2S 3A1, Canada, Email: firstname.lastname@example.org
The application of organofluorine compounds is widespread with many current uses in the life sciences and medical field. As modern methods for the introduction of fluorine into molecules continue to develop, so is the growing use of fluorine and its radioisotope, fluorine-18, in the medical field. This mini review summarizes some of the major advancements pertaining to 18F radiotracers for positron emission tomography (PET) imaging and its application as a tool to aid in the diagnosis of Alzheimer’s disease and cancer. Further offered is a brief overview of synthetic methods for preparing organofluorine compounds and rise of organotrifluoroborates in 18F PET imaging.
Keywords: PET imaging; Fluorine; Radionuclide; Alzheimer’s disease; Cancer; Organotrifluoroborates
Organofluorine compounds are abundant in medicine and
society-largely by human design and chemical synthesis, not
de novo in Nature. In fact, only twenty-one fluorine-containing
metabolites among an estimated 130,000 structurally characterized
natural products are known [1-3]. This is in sharp contrast to
30% of agrochemicals and 20% of pharmaceuticals containing
fluorine, including several of the top drugs, e.g., 5-fluorouracil,
fluoxetine (Prozac), paroxetine (Paxil), ciprofloxacin (Cipro),
mefloquine, and fluconazole . Today, thanks to advancements in
chemical synthesis, the incorporation of fluorine into compounds
is becoming a simpler task that is enabling innovations in
medicine and bio-oriented applications. With this has been major
advancements, such as the ever-useful non-invasive positron
emission tomography (PET) imaging technique [5,6]. In this regard,
the use of unnatural radionuclide fluorine-18 (18F), with a fleeting
half-life of 109.8 min/h, has a prominent status in 18F PET imaging
[7-11]. Contributing to this widespread use is the small size (van
der Waals radius of 1.47 Å) and high Pauling electronegativity of
3.98 of the fluorine atom, referred to by some as a “small atom
with a big ego.” What is more, fluorine has the ability to influence
molecular conformation and improve metabolic stability, solubility,
permeability, and protein binding [12,13]. Meanwhile, 18F is among
one of the safest radioisotope probes owing to minimal radiation
exposure upon administration, low-toxicity, and high signal-tonoise
In this short review, we touch upon the synthesis of fluorine-18 labeled organofluorine compounds and discuss select usages in 18F PET imaging for two widespread diseases, namely cancer and Alzheimer’s disease. Additionally, we delve into timely developments surrounding the utility of organotrifluoroborate compounds and their promise in 18F PET imaging by highlighting a few examples. While by no means comprehensive, we hope this mini review provides a helpful resource for understanding the role of organofluorine compounds in 18F PET imaging, thus, bridging the health science and chemistry fields.
One longstanding obstacle to 18F PET imaging remains synthetic methods for rapid incorporation of 18F into bio-relevant moleculesstemming from the short half-life of this radionuclide. In this context, classic preparative methods (syntheses) for incorporating fluorine into molecules include the use of fluorine gas, hydrogen fluoride, alkali-metal halides and/or the Balz–Schiemann reaction, which require harsh conditions making them unsuitable or challenging to implement . Alternatively, nucleophilic aromatic substitution (SNAr) is a more viable means for preparing various 18F aryl-containing, metabolically-stable organofluorine compound radiotracers, e.g., [18F]altanserin, [18F]haloperidol and [18F] flumazenil; however, SNAr reactions are often plagued by excessive heating and moderate reaction times (e.g., > 100oC for a period of 30 minutes) [16-18]. Although some of these strategies for late-stage 18F incorporation into molecules are not ideal, recent technologies are enabling this reactivity to occur under more mild conditions and fast reaction times, e.g., microwave heating as opposed to conventional heating. Complementing this alternative form of heating is the growing use of diaryliodonium salts, dediazoniation reactions, electrochemical radiofluorination and exploitation of nonhazardous electrophilic fluorine sources, e.g., [18F]Selectfluor .
18F PET imaging has proven its merit as a diagnostic tool, with its use in helping diagnose two pervasive illnesses, namely Alzheimer’s disease and cancer, thus, making them exemplar cases for discussion. Turning first to Alzheimer’s disease, this neurodegenerative disorder affects approximately 6% of the global population over the age of 65 and accounts for around 80% of all dementia diagnoses, with an associated cost for treatment in excess of $500 billion annually [20-22]. Alzheimer’s disease is characterized by a combination of neuropathological features, including extracellular brain amyloidosis, intracellular tau accumulation, brain atrophy and cell depletion . As this is a progressive disorder, early-stage identification is of the utmost importance. To date, the majority of PET imaging approaches have targeted amyloid-β aggregates due to its indisputable specific association with Alzheimer’s disease . In this context, 18F-labeled amyloid radiotracers-[18F]florbetaben , [18F]flutemetamol and [18F]florbetapir-have been implemented into clinical practice with promising outcomes. Although these radiotracers have shown remarkable accuracy in amyloid-β detection to assist in diagnosis, they exhibit additional white matter binding, thus, decreasing specificity to amyloid-β [25,26]. While the frontiers of science are clearly being pushed forward with respect to the development of 18F radiotracers, this is still an imperfect process; there is an obvious need to implement more efficient 18F radiotracers that manifest in more specific binding to amyloid-β.
Cancer, as the second leading cause of deaths worldwide, has a major impact on society as attested for by an estimated 9.6 million deaths in 2018. Globally, 1 in 6 deaths results from cancer, and by 2030 the number of new cancer cases per year is expected to rise to 23.6 million. This abnormal, uncontrollable cell growth and proliferation, otherwise known as cancer, has over 227 subtypes. In men, the highest percentages of cancer types occur in the prostate, lung and bronchus, colon and rectum, and urinary bladder, while in women cancer prevalence is highest in the breast, lung and bronchus, colon and rectum, uterine corpus, and thyroid. In contrast, children are most susceptible to cancers that target blood, the brain or lymph nodes . Some conventional methods for monitoring prognosis and treatment of cancer include radiography, ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) . More recently, [18F]fluorodeoxyglucose -positron emission tomography (18F-DG PET) has emerged as an effective tool for characterizing tumors based on biochemical changes at the molecular level . What is more, its use continues to grow with the number of 18F-DG PET scans performed in the United States alone having increased nearly 9-fold in 2010. Although 18F-DG is the most commonly employed radiotracer for PET imaging (96% of PET studies in 2011 used 18F-DG), it has limitations in assessing several relevant tumors, such as prostate cancer . Moreover, 18F-DG PET scans are limited to simple metrics like maximum standardized uptake value, metabolic tumor volume, or total lesion glycolysis, which have limited predictive value. Therefore, there is a pressing need for the development and clinical application of different PET radiopharmaceuticals [31,32]. To meet this need, several newer agents have been studied in humans, including radiotracers classified by the metabolic processes they target, e.g., (18F-FLT), hypoxia (18F-FMISO), apoptosis (18F-ML-10), protein synthesis (18F-FET), membrane metabolism (11C choline), and tumor-specific agents (18F-FES) .
One significant breakthrough in 18F PET imaging has been the advancement of 18F labeled organotrifluoroborate imaging agents (e.g., 18F containing aryl trifluoroborates) [33,34]. Critical to the use of organotrifluoroborates as imaging agents, however, is chemical stability to hydrolytic defluorination resulting in free fluoride producing unwanted background signals making 18F detection difficult. Towards improving the stability of organotrifluoroborates, several strategies have emerged over the years. For example, Perrin et al. have developed electron-deficient aryl trifluoroborates (ArBF3) having reduced hydrolytic defluorination rates as attested for by the half-lives (t1/2) of 43 ± 4 min vs. 2 ± 0.04 min for 2,6-difluorophenyltrifluoroborate and phenyl trifluoroborate under identical conditions . In extending ArBF3 stability further, onium ion stabilized trifluoroborates have been reported, wherein ammonium trifluoroborates were proven effective as in vivo imaging agents [36,37]. As a recent entry, we have reported stability studies and the synthesis of bis(amino)cyclopropenium trifluoroborate (BAC-BF3) adducts having remarkable stabilities toward hydrolysis, and presumable high lipophilic character, making them attractive targets for future 18F PET imaging applications (Figure 1) . Taken together, these promising qualities provide a strong impetus for the development of new synthetic methods tailored to the design of 18F radiolabeled organotrifluoroborate molecules for 18F PET imaging and ongoing research in our group is exploring this aspect.
Figure 1:A series of BAC-BF3 compounds reported by Dudding and co-workers with variable substituents bound to the core cyclopropenium ring .
In this mini review, coverage of critical aspects relating to the synthesis of organofluorine compounds and application of the 18F isotope in PET imaging for Alzheimer’s disease and cancer was provided. Furthermore, organotrifluoroborates were also highlighted as promising molecules in the context of 18F labeling that have seen particular growth in recent years. It is our hope this mini review, and the literature citations herein, will influence the future design of organofluorine radiotracers for improving current issues in the medical field.
T.D. acknowledges financial support from the Natural Science and Engineering Research Council (NSERC) Discovery grant (2019- 04205) and Brock University.
Bio chemistryUniversity of Texas Medical Branch, USA
Department of Criminal JusticeLiberty University, USA
Department of PsychiatryUniversity of Kentucky, USA
Department of MedicineGally International Biomedical Research & Consulting LLC, USA
Department of Urbanisation and AgriculturalMontreal university, USA
Oral & Maxillofacial PathologyNew York University, USA
Gastroenterology and HepatologyUniversity of Alabama, UK
Department of MedicineUniversities of Bradford, UK
OncologyCirculogene Theranostics, England
Radiation ChemistryNational University of Mexico, USA
Analytical ChemistryWentworth Institute of Technology, USA
Minimally Invasive SurgeryMercer University school of Medicine, USA
Pediatric DentistryUniversity of Athens , Greece
The annual scholar awards from Lupine Publishers honor a selected number Read More...
We know the financial complexity of Individual read more...
The annual scholar awards from Lupine Publishers honor a selected number read more...